Methods for determining binding of an analyte to a receptor
AssigneeGenentech, Inc.
InventorsEsohe Ekinaduese Idusogie, Michael George Mulkerrin, Leonard G. Presta, Robert Laird Shields
Life of this patent
Estimating the term…
Abstract
A variant of a polypeptide comprising a human IgG Fc region is described, which variant comprises an amino acid substitution at amino acid position 329, or at two or all of amino acid positions 329, 331 and 322 of the human IgG Fc region. Such variants display altered effector function. For example, C1q binding and/or complement dependent cytotoxicity (CDC) activity may be reduced or abolished in the variant polypeptide. The application also describes an immune complex and an assay for determining binding of an analyte, such as an Fc region-containing polypeptide, to a receptor.
Claims9
A method for determining binding of an analyte to a receptor comprising the following steps performed sequentially:
- (a) forming a molecular complex between the analyte and a first target molecule, wherein the first target molecule is different from the analyte and comprises at least two binding sites for the analyte, and wherein the molecular complex comprises three analyte molecules and three first target molecules;
- and
- (b) determining binding of the molecular complex of step (a) to the receptor.
A method for determining binding of an analyte to a receptor comprising the following steps performed sequentially:
- (a) forming a molecular complex between the analyte, a first target molecule, which is different from the analyte, and a second target molecule, wherein the first target molecule comprises at least two binding sites for the analyte, and the second target molecule comprises at least two binding sites for the first target molecule;
- and
- (b) determining binding of the molecular complex of step (a) to the receptor.
Dependencies are inferred from the claim text.